**7th Translational Research Conference**
**Lymphoid Malignancies**
October 20-22, 2023 - Estoril, Portugal
Chairpersons : Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt

## Friday, October 20, 2023

**08:30–08:40 Welcome**

**SESSION I – Biology of diffuse large B-cell lymphoma subtypes**
**Chairs: David Scott (Vancouver) and Louis Staudt (Bethesda)**

| | | |
|---|---|---|
| 08:40-08:45 | Introduction | David Scott (Vancouver)<br>Louis Staudt (Bethesda) |
| 08:45-09:00 | Building lymphoma diffuse large B-cell lymphoma models | Daniel Hodson (Cambridge) |
| 09:00-09:05 | *Discussion* | |
| 09:05-09:20 | Molecular subtypes of diffuse large B-cell lymphoma | Louis Staudt (Bethesda) |
| 09:20-09:25 | *Discussion* | |
| 09:25-09:40 | High grade B-cell lymphoma | David Scott (Vancouver) |
| 09:40-09:45 | *Discussion* | |
| 09:45-09:52 | **Selected brief oral communication:**<br>Targeting N-linked glycosylation for the therapy of aggressive lymphomas | Sebastian Scheich (Bethesda) |
| 09:52-09:55 | *Discussion* | |
| 09:55-10:25 | *Panel discussion* | |

***10:25-10:55 Coffee Break***

**SESSION II – Novel molecular lymphoma subtypes**
**Chairs: Javeed Iqbal (Omaha) and Catherine Wu (Boston)**

| | | |
|---|---|---|
| 10:55-11:00 | Introduction | Javeed Iqbal (Omaha)<br>Catherine Wu (Boston) |
| 11:00-11:15 | Single cell analytics in lymphoid malignancies –<br>A conceptual overview | Catherine Wu (Boston) |
| 11:15-11:20 | *Discussion* | |
| 11:20-11:35 | Modelling of COO in T-cell lymphoma | Teresa Palomero (New York) |
| 11:35-11:40 | *Discussion* | |

| | | |
|---|---|---|
| 11:40-11:55 | T-cell lymphoma subtypes | Javeed Iqbal (Omaha) |
| 11:55-12:00 | *Discussion* | |
| *12:00-12:07* | **Selected brief oral communication:** Refining the genetic landscape of paediatric and young adult aggressive B-cell lymphoma by a morphological and molecular integrative approach | Sara Mato (Barcelona) |
| *12:07-12:10* | *Discussion* | |
| *12:10-12:40* | *Panel discussion* | |
| ***12:40-14:35*** | ***Lunch*** | |

**SESSION III – Epigenetic and genetic regulation of clonal lymphoma evolution**
**Chairs: Silvia Bea (Barcelona) and Ari Melnick (New York)**

| | | |
|---|---|---|
| 14:35-14:40 | Introduction | Silvia Bea (Barcelona)<br>Ari Melnick (New York) |
| 14:40-14:55 | Mechanisms of B cell lymphomagenesis: Pervasive hypermutation of super-enhancers dysregulates oncogene expression | Riccardo Dalla-Favera (New York) |
| 14:55-15:00 | *Discussion* | |
| 15:00-15:15 | Epigenetic dysregulation in diffuse large B-cell lymphoma | Ari Melnick (New York) |
| 15:15-15:20 | *Discussion* | |
| 15:20-15:35 | Landscape and evolution in mantle cell lymphoma | Silvia Bea (Barcelona) |
| 15:35-15:40 | *Discussion* | |
| *15:40-15:47* | **Selected brief oral communication***:* Elucidating the mechanism of the tumour suppressor gene, GNA13, in aggressive B cell lymphomas | Rachel Fenner (Cambridge) |
| *15:47-15:50* | *Discussion* | |
| 15:50-16:20 | *Panel discussion* | |
| ***16:20-16:50*** | ***Coffee break*** | |

**SESSION IV – Cellular immune therapies**
**Chairs: Catherine Bollard (Washington) and Jason Westin (Houston)**

| | | |
|---|---|---|
| 16:50-16:55 | Introduction | Catherine Bollard (Washington)<br>Jason Westin (Houston) |
| 16:55-17:10 | CAR T-cells for B-cell lymphoma - state of the art | Jason Westin (Houston) |
| 17:10-17:15 | *Discussion* | |
| 17:15-17:30 | Novel conceptual design of innovative (CART and NK cell) constructs for lymphoma | Catherine Bollard (Washington) |
| 17:30-17:35 | *Discussion* | |

17:35-17:50 "Off-the-shelf" CAR constructs David Miklos (Stanford)
17:50-17:55 *Discussion*

17:55-18:02 **Selected brief oral communication :**
Targeting the myeloid-macrophage cell compartment through CSF1R-blockade enhances CD19-CAR T-cell efficacy in high-grade B-cell lymphoma David Stahl (Cologne)
18:02-18:05 *Discussion*

18:05-18:35 *Panel discussion*

**18:40 – 19:40 Mentored Poster Walks and Welcome Get Together stand up buffet dinner**
**Clinical poster leaders: Laurie Sehn (Vancouver) & Jason Westin (Houston)**
**Biology posters leaders: Silvia Bea (Barcelona) & David Scott (Vancouver)**

## Saturday, October 21, 2023

**08:40-09:40 3 Simultaneous Meet the Expert sessions (non-clinical)**

1, The challenges and potential of population-based tumor registries David Scott (Vancouver)
2, Molecular predictors for follicular lymphoma Gilles Salles (New York)
3, Biological insights in Hodgkin lymphoma Margaret Shipp (Boston)

***09:40-10:10 Coffee break***

**SESSION V – Monoclonal antibodies & non-cellular immune therapies**
**Chairs: Gilles Salles (New York) and Laurie Sehn (Vancouver)**

10:10-10:15 Introduction Gilles Salles (New York)
Laurie Sehn (Vancouver)

10:15-10:30 Antibody-drug conjugates in relapsed/refractory non-Hodgkin lymphoma
Laurie Sehn (Vancouver)
*10:30-10:35 Discussion*

10:35-10:50 Bispecific antibodies in non-Hodgkin lymphoma Martin Hutchings (Copenhagen)
*10:50-10:55 Discussion*

10:55-11:10 Tafasitamab CD19 + Len and novel bispecific Ab strategies Gilles Salles (New York)
11:10-11:15 *Discussion*

11:15-11:30 PI3K inhibitors Georg Lenz (Münster)
11:30-11:35 *Discussion*

11:35-11:42 **Selected brief oral communication** *:*
Durable complete remissions with subcutaneous epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma:
long-term results from the phase 2 expansion cohort of the EPCORE NHL-1 trial
Martin Hutchings (Copenhagen)
11:42-11:45 *Discussion*

11:45-12:15 *Panel discussion*

***12:15-14:10 Lunch***

***13:00-14:00*** **SATELLITE SYMPOSIUM:**
**Working towards precision medicine approaches for CLL**
**Chair:** Raúl Córdoba (Madrid)
**Speakers**: Alessandra Tedeschi (Milan), Xose Antón Suárez Puente (Oviedo)

*This educational symposium is organized and funded by BeiGene*

**SESSION VI – Lymphoma cell interactions in the tumor microenvironment**
**Chairs: Margaret Shipp (Boston) and Karin Tarte (Rennes)**

| | | |
|---|---|---|
| 14:10-14:15 | Introduction | Margaret Shipp (Boston)<br>Karin Tarte (Rennes) |
| 14:15-14:30 | Microenvironment of chronic lymphocytic leukaemia | Silvia Deaglio (Turin) |
| 14:30-14:35 | *Discussion* | |
| 14:35-14:50 | Microenvironment of and inflammatory signaling in diffuse large B-cell lymphoma | Margaret Shipp (Boston) |
| 14:50-14:55 | *Discussion* | |
| 14:55-15:10 | Microenvironmental niche of indolent lymphoma | Karin Tarte (Rennes) |
| 15:10-15:15 | *Discussion* | |
| 15:15-15:22 | **Selected brief oral communication**<br>Epcoritamab SC + $R^2$ in patients with relapsed or refractory follicular lymphoma yields high response rates regardless of POD24 status: updated results from EPCORE NHL-2 | Martin Hutchings (Copenhagen) |
| 15:22-15:25 | *Discussion* | |
| 15:25-15:55 | *Panel discussion* | |

***15:55-16:25 Coffee break***

**SESSION VII – Small molecular pathway inhibitors**
**Chairs: Alexey Danilov (Duarte) and Mark Roschewski (Bethesda)**

| | | |
|---|---|---|
| 16:25-16:30 | Introduction | Alexey Danilov (Duarte)<br>Mark Roschewski (Bethesda) |
| 16:30-16:45 | BTK inhibitors in aggressive lymphoma | Mark Roschewski (Bethesda) |
| 16:45-16:50 | *Discussion* | |
| 16:50-17:05 | Function and targeting of MALT1 in aggressive lymphomas | Daniel Krappmann (Neuherberg) |
| 17:05-17:10 | *Discussion* | |

17:10-17:25 CDK9 inhibitors for double refr. Ibru venetoclax refractory lymphoma/chronic lymphocytic leukaemia — Alexey Danilov (Duarte)
17:25-17:30 *Discussion*

17:30-17:37 **Selected brief oral communication :**
Selective targeting sumoylation with TAK-981 (subasumstat) induces metabolic reprogramming and restricts growth of aggressive non-Hodgkin lymphoma (NHL) in preclinical models — Alexey Danilov (Duarte)
17:37-17:40 *Discussion*

*17:40-18:10* *Panel discussion*

## Sunday, October 22, 2023

**07:30-08:30** **3 Simultaneous Breakfast Meet the Expert Sessions (Clinical)**

1, Practical aspects of integrating bispecifics into clinical care — Martin Hutchings (Copenhagen)
2, Rational development of combination therapies for lymphoma — Mark Roschewski (Bethesda)
3, Use of ctDNA in the clinic — Ash Alizadeh (Stanford)

**SESSION VIII – Combination therapies**
**Chairs: Paolo Ghia (Milan) and Mark Roschewski (Bethesda)**

08:35-08:40 Introduction — Paolo Ghia (Milan), Mark Roschewski (Bethesda)

08:40-08:55 Venetoclax in combination with other agents in chronic lymphocytic leukaemia and non-Hodgkin lymphoma — Michael Hallek (Cologne)
08:55-09:00 *Discussion*

09:00-09:15 Timing and duration of targeted therapies, continuous versus MRD-guided versus time-limited? — Paolo Ghia (Milan)
09:15-09:20 *Discussion*

09:20-09:35 Novel combination therapy — Mark Roschewski (Bethesda)
09:35-09:40 *Discussion*

09:40-09:47 **Selected brief oral communication :**
Efficacy of drug-induced polyploidy and BCL-2 Inhibition in lymphoma treatment — Ana Portelinha (New York)
09:47-09:50 *Discussion*

09:50-10:20 *Panel discussion*

***10:20-10:50*** ***Coffee break***

**SESSION IX – Use of circulating tumor DNA for diagnostic and therapeutic monitoring**
**Chairs: Ash Alizadeh (Stanford) and Michael Hallek (Cologne)**

| | | |
|---|---|---|
| 10:50-10:55 | Introduction | Ash Alizadeh (Stanford)<br>Michael Hallek (Cologne) |
| 10:55-11:10 | Circulating tumor DNA as predictor for survival in diffuse large B-cell lymphoma | Ash Alizadeh (Stanford) |
| 11:10-11:15 | *Discussion* | |
| 11:15-11:30 | Circulating tumor DNA in primary CNS lymphoma | Stefan Alig (Stanford) |
| 11:30-11:35 | *Discussion* | |
| 11:35-11:50 | Circulating tumor DNA in chronic lymphocytic leukaemia | Moritz Fürstenau (Cologne) |
| 11:50-11:55 | *Discussion* | |
| *11:55-12:02* | **Selected brief oral communication :**<br>Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA | Jan-Michel Heger (Cologne) |
| *12:02-12:05* | *Discussion* | |
| *12:05-12:35* | *Panel discussion* | |
| ***12:35-12:45*** | ***Closing Remarks*** | |

**MEETING CLOSURE**